WELCOME!

- Introduction to IDPH Staff
- Interaction
- Bingo cards & awards
The Illinois Chapter, American Academy of Pediatrics is accredited by the Illinois State Medical Society (ISMS) to provide continuing medical education for physicians.

The Illinois Chapter, American Academy of Pediatrics designates this live conference for a maximum of 5 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners can submit Certificates of Attendance to their accrediting board to claim credit for participation in the live webinars.
<table>
<thead>
<tr>
<th>Name and Credentials</th>
<th>Please select your role in this activity:</th>
<th>Was there a relevant financial disclosure?</th>
<th>List of mitigated disclosures.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allison Rankovich</td>
<td>Content Reviewer</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Daniel Goodman</td>
<td>Faculty/Presenter IDPH</td>
<td>Yes</td>
<td>Stocks in Pfizer &amp; McKesson</td>
</tr>
<tr>
<td>Pamela Linder</td>
<td>Content Reviewer</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Jennifer Burns</td>
<td>Faculty/Presenter</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Alison Lind, MPH</td>
<td>Faculty/Presenter Content Reviewer</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Karyn Lyons, MS, RN</td>
<td>Staff Content Reviewer</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Sharon E Hovey, MD</td>
<td>Faculty/Presenter Planning Committee Member</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Mya Pierson</td>
<td>Planning Committee Member</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Shefali Parikh</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Katrina Galati, MPH, CHES</td>
<td>Planning Committee Member</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>LaDaryl Hale</td>
<td>Planning Committee Member</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Alexandra Arca, MPH</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Stephanie Atella, MPH, CHES</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Magale Avitia, MPH, CHES</td>
<td>Content Reviewer Content Developer</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Caroline Werenskold, MPH</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Brandi Vogt, CHES</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Monica Del Ciello, MPH</td>
<td>Staff</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Tricia Scerba, MD MBA</td>
<td>Faculty/Presenter</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Joyce M Jones King, MD</td>
<td>Faculty/Presenter</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
AGENDA

• 8:15am – 8:45am: Check-in & Breakfast
• 8:45am – 10:45am: 2024 ACIP Vaccine Schedules & Respiratory Virus Season
• 10:45am – 11am: Break
• 11am – 12:15pm: IDPH VFC Program
• 12:15pm – 1pm: Networking & Lunch
• 1pm – 1:45pm: Vaccine Hesitancy
• 1:45pm – 2:45pm: Group Discussion
• 2:45pm – 3pm: Questions & Closing
IDPH VFC PROGRAM
Monica Del Ciello, MPH
AFTER THIS SESSION:

Participants will be able to:

1. Use the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) portal to order and maintain vaccines.

2. Describe inventory reconciliation best practices for I-CARE and VFC mandates.

3. Implement effective vaccine storage and handling practices and keep vaccine waste to a minimum.
OVERVIEW - VFC PROGRAM

• Federally funded by the Centers for Disease Control and Prevention (CDC).
• Provides vaccines at no cost to children who may not otherwise get them.
• Eligibility: 18 years and younger and one of the following
  • Uninsured or Underinsured.
  • Medicaid Title 19 or 21 eligible.
  • American Indian or Alaskan Native.
• Children who are underinsured can access VFC vaccines at federally qualified health centers (FQHCs), rural health clinics, and some local health departments that are deputized by FQHCs or RHCs.
Vaccines for Children
Protecting America’s children every day

The Vaccines for Children (VFC) program helps ensure that all children have a better chance of getting their recommended vaccines. VFC has helped prevent disease and save lives.

CDC estimates that vaccination of children born between 1994 and 2021 will:

- prevent 472 million illnesses
  (29.8 million hospitalizations)
- help avoid 1,052,000 deaths
- save nearly $2.2 trillion in total societal costs
  (that includes $479 billion indirect costs)

Visit www.cdc.gov/vaccines/vfcprogram/ for more information.

Updated CDC analyses using methods from "Vaccines from Immunization: The Vaccines for Children Program—United States, 1994-2017."
I-CARE

• IL’s Immunization Information Systems (IIS).
• An electronic web-based immunization data registry operated by IDPH.
• All VFC providers must be enrolled in I-CARE.
• Must be able to provide individual patient immunization records.
• Immunization records can be entered manually or electronically through the provider’s electronic medical record.
I-CARE ENROLLMENT

- Now done completely online, no paperwork.
  - Decrease turnaround time and prevent duplicate submissions.
- Easier to add/modify new users and organizations.
- Documents needing signature are automatically sent via DocuSign.
• New tab on I-CARE site that has links for submitting help requests.
I-CARE & HL7

• Share Electronic Health Record (EHR) with I-CARE using HL7 data exchange.
  • Contact EHR vendor to determine if your system is HL7 compatible.
  • May need to acquire an additional interface for your EHR to send and exchange immunization data.

For more information on HL7 please visit I-CARE HL7 Specifications. If you have questions, contact dph.icare@illinois.gov.
VFC SITE REQUIREMENTS

• Be licensed in Illinois to administer vaccines to children 18 years old and younger.

• Be willing and able to follow all VFC program requirements, policies, and procedures, including participation in site visits and educational opportunities.

• Have capacity to order, receive, manage, store, and monitor the temperature of public vaccines.

• Be open at least four consecutive hours for three days a week to receive VFC vaccines.

• Record keeping and reporting adverse reactions to VAERS and MedWatch.
CDC’s Provider Agreement.

• The provider signing the Provider Agreement for a multi-provider practice must have the authority to sign on behalf of the entity.

• All licensed health care providers (MD, DO, NP, PA, pharmacist) at your facility who have prescribing authority must be listed with professional license numbers and individual NPI numbers (VFC Enrollment Form).
PROVIDER PROFILE

• A Provider Population Profile must be submitted when enrolling and updated annually or when order patterns indicate a change.
  • IDPH will send an update request via SmartSheets in April 2025.

• All VFC programs must determine individual provider populations served and associated vaccine need by funding type.

• This ensures publicly purchased vaccines are distributed in amounts representing the patient population served and to adjust as populations change.
**ANNUAL EDUCATION**

**ANNUAL** education on vaccine storage and handling training is required:

- You Call The Shots – [Module 10 – Storage and Handling](#).
- You Call the Shots – [Module 16 – Vaccines for Children Program](#).

- All staff members who receive vaccine deliveries and/or handle or administer vaccines should complete education.

- Documentation of **BOTH** training modules must be documented in the vaccine management plan and submitted with annual enrollment (reviewed during site visits).
BI-ANNUAL RECERTIFICATION

• All VFC providers must recertify their enrollment every other year (new change from annual) to continue participating in the VFC program.
  • Timing moving from Winter to Spring.
  • Submitted in I-CARE.

• Additionally, providers should:
  • Review and Agree to the VFC Eligibility and the VFC Loss and Replacement Policies.
  • Review, sign, and upload the VFC Provider Agreement.

• Remember: updating the provider profile and completing required education is still annual!
RECORD KEEPING

Distribution of Vaccine Information Statements (VISs)

• Must be provided each time a National Vaccine Injury Compensation Program (VICP) covered vaccine is administered*
• Given to parent, legal guardian, or patient (non-minor) to keep.*
• Must be the most current version.†
• Can provide other written or audio-visual materials as necessary.

Immunize.org: VISs (available in 47 languages)

Documentation of Vaccine Administration

• Vaccine manufacturer, lot number, and date of administration.*
• Name and business address of the physician administering the vaccine.*
• Vaccine information statement version date and date provided. †
• Site (deltoid), route of administration (intramuscular), and expiration date of vaccine.

*Required under the National Childhood Vaccine Injury Act, foreign VISs may not be up to date
†Required under CDC instructions

KNOWLEDGE CHECK

What is the minimum amount of time that VFC records should be maintained?

A. 1 year
B. 3 years
C. 5 years
D. Forever
STAFF AND TRAINING – VACCINE COORDINATORS

• Primary and backup vaccine coordinators:
  o Responsible for ordering, receiving, rotating, and monitoring vaccines.
  o Must be fully trained on routine and emergency SOPs for vaccine ordering, storage, handling, transport, and inventory management.

• More information about coordinator responsibilities can be found in the Vaccine for Children Program Manual for Illinois VFC Providers.

• Notify IDPH when there is a change in vaccine coordinators or medical director. Vaccine Program Site Updates
PROVIDER UNENROLLMENT

• Providers who wish to terminate the provider agreement must:
  o Complete unenrollment form.
  o Stop using VFC vaccines as of the unenroll date.
  o Return any unused VFC vaccines within 30 days.

• Examples of why IDPH may terminate the provider agreement include:
  o Provider has not ordered vaccine in the past 12 months.
  o A provider is on the List of Excluded Individual and Entities (LEIE) list maintained by Office of the Inspector General.
  o Failure to comply with requirements.
SITE VISITS

- Enrollment
- Compliance
- Storage and Handling
- Education
ENROLLMENT VISITS

• All providers (newly enrolling or re-enrolling after an absence) must have an enrollment site visit before being approved to order VFC vaccines.

• This visit is to educate providers on:
  o VFC program requirements.
  o Proper vaccine storage and handling.
  o Appropriate resources to implement requirements.

• Providers should be prepared for follow-up visits during the first year.
COMPLIANCE VISITS

• Sites will be enrolled and active in the VFC program for 3-6 months before receiving a compliance site visit.

• This visit includes a review of and ensuring compliance with:
  o Provider Profile
  o Vaccine ordering and inventory management
  o Policies, procedures and vaccine management plan
  o Vaccine storage and handling equipment, procedures, and documentation
  o VFC screening requirements and billing practices
  o All ACIP vaccines are available to VFC-eligible patients
  o VFC-related document retention
STORAGE AND HANDLING VISITS

• May be scheduled or *unannounced*.

• IDPH must complete *unannounced* storage and handling site visits for a percentage of providers each year.

• This visit includes a review of and ensuring compliance with:
  o Vaccine inventory management
  o Vaccine storage and handling equipment and monitoring
  o Vaccine storage and handling procedures and Vaccine management plan
  o Appropriate storage and handling related documentation

• Vaccines purchased with state and federal funds that are deemed non-viable due to provider negligence must be **replaced** on a dose-for-dose basis with privately purchased vaccines.
FRAUD AND ABUSE

• Examples of fraud and abuse:
  • Providing VFC vaccines to non-VFC eligible children.
  • Billing a patient or third party for a VFC vaccine.
  • Denying VFC eligible children a VFC vaccine due to inability to pay an administration fee.
  • Failing to screen for and document eligibility at each visit.
  • Failing to properly maintain VFC records and requirements.
  • Failing to properly store and handle VFC vaccines, etc.

• IDPH may investigate to determine intentional or unintentional fraud/misuse.
PATIENT ELIGIBILITY

• Providers must screen, document, and verify VFC eligibility before administering VFC vaccines.
• Use the MEDI system or equivalent system (with HFS 270/271 electronic transaction data).
• The Patient Eligibility Screening Form provides a means of recording responses to VFC eligibility questions.
  o The provider, parent, or guardian may complete the VFC eligibility portion of the form.
  o Verification of parent/guardian responses is not required.
## ELIGIBILITY

<table>
<thead>
<tr>
<th>VFC Eligibility Criteria</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Indian or Alaska Native (AI/AN)</td>
<td>This population is defined by the Indian Health Care Improvement Act (25 U.S.C. 1603). (AI/AN children are VFC-eligible under any circumstance.)</td>
</tr>
<tr>
<td>Medicaid-eligible</td>
<td>Children who are eligible for the Medicaid program. For the purposes of the VFC program, the terms “Medicaid-eligible” and “Medicaid enrolled” are used interchangeably.</td>
</tr>
<tr>
<td>Uninsured</td>
<td>Children not covered by any health insurance plan.</td>
</tr>
<tr>
<td>Underinsured</td>
<td>Underinsured means the child has health insurance, but the insurance policy: • Does not include any vaccines; • Does not include all vaccines recommended by the Advisory Committee on Immunization Practices (ACIP); or • Has a fixed dollar limit or cap for vaccines. Underinsured children are only eligible to receive VFC vaccines at a FQHC, RHC, or a deputized provider.</td>
</tr>
</tbody>
</table>
KNOWLEDGE CHECK

Where can underinsured VFC-eligible children receive VFC vaccines from?
A. FQHCs
B. RHC
C. LHD deputized by a FQHC or RHC
D. All of the above
DISCUSSION QUESTION

If your site is not a FQHC, RHC or deputized LHD, what should you do to help underinsured VFC-eligible children get vaccinated?
ELIGIBILITY

• American Indian/Alaska native (AI/AN) children are VFC-eligible under any circumstance.
  • Participation is voluntary.

• Children with a private primary health insurance plan with Medicaid as their secondary insurance are VFC-eligible because of their Medicaid enrollment.
BILLING - MEDICAID SECONDARY INSURANCE*

Option 1: The provider can administer VFC vaccines and bill Medicaid for the administration fee.

Considerations:
• Easiest way for a provider to use VFC vaccines and bill Medicaid for the administration fee.
• No out-of-pocket costs to the parent for the vaccine or the administration fee.

Option 2: The provider can administer private stock vaccines and bill the primary insurance carrier for both the cost of the vaccine and the administration fee.

Considerations:
• Provider may be reimbursed a higher dollar amount if privately purchased vaccine is administered and both the vaccine and the administration fee are billed to the primary insurer.

*Consider these options for AI/AN populations that qualify for VFC under a second category as the family may be responsible for administration fees.
<table>
<thead>
<tr>
<th>Child’s Insurance Status</th>
<th>VFC-Eligible?</th>
<th>VFC Eligibility Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrolled in Medicaid</td>
<td>Yes</td>
<td>Medicaid (V02).</td>
</tr>
<tr>
<td>Has private health insurance plan with Medicaid as secondary insurance.</td>
<td>Yes</td>
<td>Medicaid (V02). The provider should choose the option that is most cost-effective for the family.</td>
</tr>
<tr>
<td>Has health insurance covering all vaccines but has not yet met plan’s deductible or paid for other services received at visit.</td>
<td>No</td>
<td>Insured (V01). This applies even when primary insurer would deny reimbursement for the cost of the vaccine and its administration because the plan’s deductible has not been met.</td>
</tr>
<tr>
<td>Has health insurance covering all vaccines but has not yet met plan’s deductible or paid for other services received at visit and has Medicaid as secondary insurance.</td>
<td>Yes</td>
<td>Medicaid (V02).</td>
</tr>
<tr>
<td>Has health insurance covering all vaccines, but the plan has a fixed dollar limit or cap on amount that it will cover.</td>
<td>Yes</td>
<td>Insured (V01) until the fixed dollar limit is met. Underinsured (V05) after the fixed dollar limit is reached.</td>
</tr>
<tr>
<td>Has an insurance plan that does not cover all ACIP-recommended vaccines.</td>
<td>Yes</td>
<td>Underinsured (V05). Child can only receive vaccines not covered by the plan.</td>
</tr>
<tr>
<td>Has health insurance, but plan does not cover any vaccines.</td>
<td>Yes</td>
<td>Underinsured (V05). With implementation of ACA, this situation should be rare.</td>
</tr>
<tr>
<td>Has no health insurance coverage.</td>
<td>Yes</td>
<td>Uninsured (V03).</td>
</tr>
<tr>
<td>Has private health insurance that covers all vaccinations and is AI/AN.</td>
<td>Yes</td>
<td>AI/AN (V04). The provider should choose the eligibility category most cost effective for the family.</td>
</tr>
<tr>
<td>Has Medicaid and is AI/AN.</td>
<td>Yes</td>
<td>Medicaid (V02) or AI/AN (V04). Providers should use Medicaid for the administration fee (least out-of-pocket expense for family).</td>
</tr>
</tbody>
</table>
NO CHARGE FOR VACCINES

• Patients and families cannot be charged for publicly purchased vaccines.

• Do not bill any individual or other third-party payer for the cost of VFC-supplied or other vaccines purchased through CDC federal contracts.
ADMINISTRATION FEES

- Bill only Medicaid for the administration fee for VFC-eligible children enrolled in Medicaid (per vaccine and not per antigen).
- The vaccine administration fee for non-Medicaid VFC-eligible children must not exceed $23.87 per dose.
- VFC providers may issue a single bill for the administration fee for non-Medicaid VFC-eligible children within 90 days of vaccine administration.
- Unpaid VFC vaccine administration fees may not be sent to collections and VFC providers may not refuse to vaccinate an eligible child whose parents have unpaid vaccine administration fees.
KNOWLEDGE CHECK

The vaccine administration fee for non-Medicaid VFC-eligible children must not exceed how much per dose?

A. $6.40  
B. $16.71  
C. $21.62  
D. $23.87
VACCINE MANAGEMENT

• Providers should follow VFC storage and handling requirements based on CDC’s Vaccine Storage and Handling Toolkit including:
  • Ordering vaccines
  • Utilizing required equipment
  • Digital data loggers
  • Vaccine cold chain
VACCINE MANAGEMENT PLAN

- Contact info for current primary and backup vaccine coordinators.
- Proper storage and handling practices.
- Procedures for vaccine ordering, receiving, inventory control, stock rotation, and handling vaccine loss and waste.
- Procedures for emergency situations (transport, equipment malfunction, power failure, and natural disaster).
- Documented training related to vaccine management.
- Provider and vaccine coordinator roles & responsibilities.
- Plans must be updated annually or more frequently as needed.
ORDERING VACCINES

• Ordering is completed through I-CARE.
• Should be up-to-date before submitting an order:
  ❑ Vaccine inventory.
  ❑ Patient immunization records.
  ❑ Temperature logs for all appliances.
  ❑ All data logger certificates of calibration are valid and not expired.
  ❑ All temperature excursions must have a vaccine incident report on file.
  ❑ Delivery hours, including specifying lunch hours or other closures.
• Order and stock enough vaccine to meet patient demand for one to three months.
KNOWLEDGE CHECK

Borrowing between public VFC & private vaccine inventory is not allowed.
A. True
B. False
VACCINE MANAGEMENT – BORROWING VACCINES

• Borrowing between public VFC & private vaccine inventory is not allowed.
• Transfers of VFC vaccine between VFC clinics are allowable with permission from IDPH and proper transport storage equipment.
  ○ (e.g., transferring short-dated vaccines to another provider that can use them)
• A transfer request form is available in I-CARE.
KNOWLEDGE CHECK

Transfers of VFC vaccine between VFC clinics are allowable with permission from IDPH and proper transport storage equipment.

A. True
B. False
VACCINE MANAGEMENT – COLD CHAIN

- Vaccine cold chain must be maintained (ensures potency and useability).
- Helps save money and avoid re-vaccination.
- Vaccine appearance is NOT a reliable indicator that vaccines have been stored in appropriate conditions.
VACCINE MANAGEMENT — RECEIVING VACCINE

• Vaccine and diluent should be immediately unpacked, stored at recommended temperatures, and documented upon arrival.

• Do not store shipment box in vaccine storage unit – the combined storage methods may be too cold.

• Check immediately for:
  • Physical damage of shipping container.
  • Correct products were received.
  • Diluent and vaccine expiration dates.
  • Cold chain monitor, if included.

Any issues should be reported within two hours to the Illinois VFC Program Services Staff at 217-785-1455. If you do not immediately reach anyone, please call again and follow up with an email to dph.vaccines@illinois.gov.
VACCINE MANAGEMENT – STORING VACCINE

- Store vaccine by funding type (check I-CARE or packing slips).
- Separate units are not required.
  - VFC: VFC eligible patients only.
  - 317: 317-eligible adults or approved outbreak response.

- Clearly label VFC and private vaccines.
- Group vaccines (pediatric, adolescent, adult).
- Label shelf space or baskets to make vaccines easy to find.
- Position vaccines or baskets 2-3 inches away from walls, floor, and other baskets.
- Store vaccines in original packaging with earliest expiration date in front.
- Diluents may be stored next to refrigerated vaccines unless manufacturer states otherwise. Never store diluents in the freezer.

Usable space for vaccine is inside dashed lines.

Do not block air vents.
Do not stack baskets on top of each other.
No vaccines in doors.
No food or beverages.
VACCINE MANAGEMENT – STORING VACCINE

• Stock rotation and removal:
  • Rotate vaccine stock so the vials with the soonest expiration date are at the front (used first).
  • Immediately remove expired vaccine from stock.

**TIP:** Determine regular intervals for rotation (i.e., weekly), including when there is a vaccine delivery.
VACCINE MANAGEMENT – REQUIRED EQUIPMENT

Purpose-built or pharmaceutical-grade refrigerators and freezers are preferred.

• Needs to be approved and met with the guidelines and re-certified by approved source.

• Stand-alone refrigerator and freezer units may also be used.

• IDPH does not allow combination household refrigerator/freezer units for storage.
  • Never store vaccine in a dorm-style or bar-style combined refrigerator/freezer unit.
VACCINE MANAGEMENT — REQUIRED EQUIPMENT

- Some purpose-built units separate public & private vaccine stock electronically.
  - If electronic, an inventory printout must be available upon request.
- Power Supply:
  - Plug in only one storage unit per electrical outlet.
  - Use a safety-lock plug or an outlet cover.
  - Post “DO NOT UNPLUG” warning signs at outlets and on storage units.
  - Label fuses and circuit breakers to alert others not to turn off these units.
  - Use caution when using power outlets that can be tripped or switched off and avoid using:
    - Built-in circuit switches (may have reset buttons).
    - Outlets that can be activated by a wall switch.
    - Multioutlet power strips.
VACCINE MANAGEMENT — REQUIRED EQUIPMENT

- Storage units should be placed in a well-ventilated room, between 68°F - 77°F, and without anything blocking them.
  - Refrigerators should maintain temps between 2°C - 8°C (36°F - 46°F).
  - Freezers should maintain temps between -50°C and -15°C (-58°F - +5°F).
  - Recommended to set temps in Celsius and record to 1 decimal place.
  - Record temperatures:
    - Any time staff are in the clinic, at least 3x/week.
    - 2x/day and the min/max temps at the start of every day.
    - Doors should always remain closed – consider using locks or alarms.
- It can take multiple days to stabilize the temp in a new or repaired unit.
  - Min and max temps should be recorded 2x/day for 2 to 7 days.
  - Once two consecutive days of temperatures are recorded within the recommended range, the unit is stable and ready for use.
KNOWLEDGE CHECK

Vaccines and food/beverages can be stored in the same unit.
A. True
B. False
VACCINE MANAGEMENT – DIGITAL DATA LOGGERS

• Digital Data Loggers (DDLs) continually monitor the temperature of vaccines.
• Data from DDLs is retrieved using special software or a website.
• DDLs must have a certificate of calibration that is current.
• Some purpose-built units have built-in DDLs. Make sure these meet all the requirements.
• A back-up DDL must be available.
VACCINE MANAGEMENT – DIGITAL DATA LOGGERS

The DDL must be equipped with:

- A temperature probe or sensor.
- An active temperature display outside the unit that can be easily read without opening the unit’s door.
- Continuous temperature monitoring and recording capabilities and capacity to routinely download data.

Additional recommended DDL features:

- Alarm for out-of-range temperatures
- Temperature display showing current, minimum, and maximum temperatures
- Low battery indicator
- Accuracy of +/-1°F (0.5°C)
- User-programmable logging interval (or reading rate) recommended at a maximum time interval of no less frequently than every 30 minutes.
VACCINE MANAGEMENT – DIGITAL DATA LOGGERS

Certificates of Calibration Testing must include:

- Model/device number.
- Serial number.
- Date of calibration (report or issue date).
- Confirmation the instrument passed testing (or instrument in tolerance).

Certificates of calibration must indicate at least one of the following:

- Conforms to ISO 17025.
- Testing was performed by an ILAC/MRS Signatory body accredited laboratory.
- Is traceable to the standards maintained by NIST.
- Meets specifications and testing requirements for the American Society for Testing and Materials (ASTM) Standard E2877 tolerance Class F (0.5 °C) or better.
LOG MAINTENANCE

• Data from DDLs should be downloaded and reviewed at least weekly.

• Temperature data logger files must be retained according to VFC records retention policy for a minimum of 3 years, so that they can be analyzed for long-term trends and/or recurring problems.

• Temperature data logger data files must be made available, upon request, within the time frame requested.
KNOWLEDGE CHECK

Purpose-built vaccine storage units with built-in DDLs that meet all requirements are an acceptable way to monitor vaccine temperature.

A. True
B. False
DISCUSSION QUESTION

Temperature Excursions: Why do these matter?
TEMPERATURE EXCURSIONS

Any temperature reading outside the recommended ranges in the manufacturers’ package inserts.

• Manufacturers will help determine if the vaccine is still viable.
• Review storage & handling policies and take the appropriate actions.
• Complete the Vaccine Incident Report in I-CARE.
• Unsure if an excursion occurred?
  • Mark vaccine “DO NOT USE!”
  • Do not use or discard until the manufacturer determines viability and IDPH VFC is contacted.
A temperature of 8.1 degrees Celsius in a refrigerator unit is a normal temperature and does not need to be reported as a temperature excursion.

A. True
B. False
VACCINE EMERGENCY RESPONSE

• Onsite generators or backup batteries can be used to prevent transporting vaccines to another storage facility in the event of an emergency like a power outage.

• Generators and backups should be tested quarterly.

• If the unit breaks down, it may be appropriate to transport.
EXPIRED, SPOILED, WASTED VACCINE

• Must be reported in I-CARE within one week of the expiration date.

• Expired and spoiled vaccines in unopened vials or unused manufacturer pre-filled syringes should be returned to McKesson Specialty within 6 months of the expiration date for Excise Tax Credit.
  - Must be unopened and in the original manufacturer vial or prefilled syringe.

• Wasted vaccines must be disposed of according to usual medical biosafety procedures and your clinic’s procedures. Includes:
  - Open vials or prefilled syringes with or without the needles attached
  - Vaccine that was drawn into a syringe
  - Vaccines compromised due to a dropped or broken container
TRANSFERRING VACCINES

• Acceptable in these cases:
  • Vaccine is six months or less from the expiration date and unable to be used by the site.
  • A VPD outbreak.
  • Clinic closure.
  • Seasonal clinic closing.

• These transfer requests will be reviewed on a case-by-case basis:
  • Vaccines are more than six months from the expiration date.
  • There is an immediate need before an order can be received.

• Cold chain must be maintained (use DDL when transferring).
MOBILE CLINICS

Same VFC storage requirements with a permanently installed unit.

• Mobile clinic should be plugged into a power source at home site location when not in use.
• Will be inspected as part of the compliance visit.
• Vaccines cannot be transported to the city of Chicago or out-of-state.
• Vaccine must be delivered to the home site.
TEMPORARY OFF-SITE VACCINE CLINICS

• Transportation, storage, and handling must meet VFC program guidelines.

• Total time for travel + clinic day should not exceed 8 hours (e.g. if transport to an off-site clinic is 1 hour each way, the clinic may run for up to 6 hours).

• Use a portable vaccine refrigerator/freezer unit or a qualified container and packout that maintains appropriate temperatures.
  • Use of the manufacturer’s shipping container or frozen water bottles is not permitted.

• Vaccine must be returned to permanent location & DDLs reviewed to ensure proper temperatures were maintained.

An off-site vaccine clinic notification form must be submitted in I-CARE 48 hours prior to the event.
SIREN ALERTS

• Siren is the emergency planning, alerting, and notification system for IDPH.
• Get rapid notifications on outbreaks, updates, and other important health alerts.
• Register at: https://www.siren.illinois.gov/
Contact the VFC program at DPH.Vaccines@illinois.gov
QUESTIONS?
BREAK

Resume at 10:10!
AFTER THIS SESSION:

Participants will be able to:

1. Outline new vaccine products and updates.
2. Apply the 2024 Advisory Committee on Immunizations Practices (ACIP) pediatric vaccination and catch-up schedules.
IMMUNIZATION SCHEDULES — WHY THEY MATTER

• Protection against roughly 20 different life-threatening diseases.

• Prevention/protection of infectious disease outbreaks.
  • Global vaccination efforts have saved an estimated 154 million lives, including 101 million infants according to the World Health Organization.
  • Vaccinations led to the eradication of smallpox, and polio is on the brink of eradication.

• Gives children protection when they are most vulnerable.
  • The measles vaccine has had the most significant impact on reducing infant deaths, accounting for 60% (94 million) of the lives saved by immunization (WHO).

• There are no other alternative studied immunization schedules approved.
An AAP study demonstrated that routine childhood vaccines help prevent unnecessary morbidity and mortality, as well as have cost-saving impacts.

- Estimated vaccines costs of $8.5 billion were entirely offset by the avoided $63.6 billion in disease-related costs.
USING THE ACIP SCHEDULE

To make vaccination recommendations, healthcare providers should:

1. Determine needed vaccines based on age (Table 1).
2. Determine appropriate intervals for catch-up, if needed (Table 2).
3. Assess for medical conditions and other indications (Table 3).
4. Review special situations (Vaccination Notes).
5. Review contraindications and precautions to vaccination (Appendix).
6. Review new or updated vaccine guidance (Addendum).
SCHEDULES

Immunization Schedules

For Healthcare Providers

Child and Adolescent Schedule
Recommended vaccination schedule for ages 18 years or younger

- Birth to 18 Years

Adult Schedule
Recommended vaccination schedule for ages 19 years or older

- 19 Years or Older

Clinical Vaccination Resources

- Download Schedule App for Healthcare Providers
- Vaccination Resources for Healthcare Providers

Interim COVID-19 Immunization Schedule for Ages 6 months and older
Guidance for COVID-19 vaccination schedules based on age and medical condition

- COVID-19 Vaccination Schedule

https://www.cdc.gov/vaccines/schedules/index.html
## APPROVING PARTNERS

<table>
<thead>
<tr>
<th>Child/Adolescent Schedule</th>
<th>Both Schedules</th>
<th>Adult Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Pediatrics (AAP)</td>
<td>American Academy of Family Physicians (AAFP)</td>
<td>American College of Physicians (ACP)</td>
</tr>
<tr>
<td>National Association of Pediatric Nurse Practitioners (NAPNAP)</td>
<td>American Academy of Physician Associations (AAPA)</td>
<td>Society for HealthCare Epidemiology of American (SHEA)</td>
</tr>
<tr>
<td></td>
<td>American College of Obstetricians and Gynecologists (ACOG)</td>
<td>American Pharmacists Association (APhA)</td>
</tr>
<tr>
<td></td>
<td>American College of Nurse-Midwives (ACNM)</td>
<td></td>
</tr>
</tbody>
</table>
# Recommended Childhood Immunization Schedule

## Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule* (2024)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Abbreviation(s)</th>
<th>Trade name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory syncytial virus monoclonal antibody (Passive)</td>
<td>RVAlmab™</td>
<td>RespiGam™</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Abbreviation(s)</th>
<th>Trade name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>Day 0/Day 38</td>
<td>Covishield™, Comirnaty™, Sputnik™, TorqueAlert™</td>
</tr>
</tbody>
</table>

- **Dengue vaccine**: TSD4B1Y, TSD4B2Y, TSD4B3Y, TSD4B4Y
- **Diphtheria, tetanus, and acellular pertussis vaccine**: DTaP-Ac
- **Hemophilus influenzae type b vaccine**: HiB (PRP-3)
- **Inactivated poliovirus vaccine**: IPV
- **Influenza vaccine (IIV)**: Flublok™, Flucelvax™, Fluarix™, Fluخطوط™, FluOptics™, FluShield™
- **Measles, mumps, and rubella vaccine**: MMR
- **Meningococcal serogroup A, C, W, Y vaccine**: MenACWY-CRM197
- **Meningococcal serogroup B vaccine**: MenB-PRP-T
- **Meningococcal serogroup B, C, W, Y vaccine**: MenACWY-TT
- **Mumps vaccine**: Mumps
- **Pneumococcal conjugate vaccine**: PCV13
- **Pneumococcal polysaccharide vaccine**: PPV23
- **Rabies vaccine**: Rabies
- **Respiratory syncytial virus vaccine**: RSV
- **Rotavirus vaccine**: Rotateq®
- **Tetanus, diphtheria, and acellular pertussis vaccine**: Tdap
- **Tetanus and diphtheria vaccine**: Td
- **Varicella vaccine**: Varivax™

## How to use the child and adolescent immunization schedule

1. **Determine recommended vaccine age**: Refer to Table 1.
2. **Determine recommended vaccination interval**: Refer to Table 2.
3. **Assess need for additional vaccines based on medical condition or other indication**: Refer to Table 3.
4. **Review vaccine types, frequencies, and considerations**: Refer to Table 4.
5. **Review contraindications for vaccine types**: Refer to Table 5.
6. **Review new or updated ACP guidance**: Refer to Table 6.

**United States 2024**

**Report**
- Suspected cases of reportable vaccine-preventable disease outbreaks to your state or local health department.
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at vaers.hhs.gov or 800-822-7970.

**Questions or comments**
- Contact the CDC via phone at 888-232-0233, or online through a chatbot at cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.

**Helpful information**

**Vaccine information statements**
- www.cdc.gov/vaccines/hcp/vaccines/index.html.

**Scan QR code for access to online schedule**

**ACIP RECOMMENDED CHILD & ADOLESCENT SCHEDULE 2024**

2024 UPDATES

Changes to Format
1. Changed headers from “Vaccine” to “Vaccines and other Immunizing Agents”.
2. Cover page: COVID-19 is added. As well as Trade name Priorix for MMR and Vaxneuvance (PCV15) for pneumococcal conjugate vaccine.

Changes to Vaccination Notes
1. RSV-mAb (nirsevimab)
2. RSVPreF (Abrysvo)
3. Jynneos (mpox)
4. Influenza
5. COVID-19
6. Meningococcal A, C, W, Y
7. Meningococcal B
8. Pneumococcal
9. Polio

Changes to Appendix
1. Column Header
2. Influenza
3. Hepatitis B
4. HPV
5. Measles, Mumps and Rubella
6. Varicella

Table 1: Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars.

To determine minimum intervals between doses, see the catch-up schedule (Table 2).

| Vaccine and Other Immunizing Agents | 0 mos | 1 mos | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19 mos | 2 yrs | 3 yrs | 4 yrs | 5 yrs | 6 yrs | 7 yrs | 8 yrs | 9 yrs | 10 yrs | 11 yrs | 12 yrs | 13 yrs | 14 yrs | 15 yrs | 16 yrs | 17 yrs |
|-----------------------------------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|
| **Respiratory syncytial virus**   | 1 dose |       |       |       | 1 dose |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |        |       |
| **Hepatitis B (HepB)**           | 1st dose | 2nd dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Rotavirus (RV): RV1 (2-dose series), RV3 (1-dose series)** | 1st dose | 2nd dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Diphtheria, tetanus, acellular pertussis (DTaP) <7 yrs** | 1st dose | 2nd dose | 3rd dose |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Haemophilus influenzae type b (Hib)** | 1st dose | 2nd dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Pneumococcal conjugate (PCV15, PCV20)** | 1st dose | 2nd dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Inactivated poliovirus (IPV) <18 yrs** | 1st dose | 2nd dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **COVID-19 (1vCOVID-mRNA, 1vCOVID-sPS)** | 1 or more doses of updated (2023-2024 Formular vaccine) (See Notes) |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Influenza (BIV4)** | Annual vaccination 1 or 2 doses |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Influenza (LAIV4)** | Annual vaccination 1 or 2 doses |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Measles, mumps, rubella (MMR)** | See Notes | 1st dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Varicella (VAR)** | See Notes | 1st dose |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Hepatitis A (HepA)** | 2-dose series, See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Tetanus, diphtheria, acellular pertussis (Tdap) >7 yrs** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Human papillomavirus (HPV)** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2 years)** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Meningococcal B (MenB-4C, MenB-FHbp)** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Respiratory syncytial virus vaccine (RSV) (Abzyme)** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |
| **Dengue (DEN4COY; 9-16 yrs)** | See Notes |       |       |       |       |       |        |        |        |        |        |       |       |       |       |       |       |       |        |        |        |        |        |       |

**Notes:**
- Range of recommended ages for all children
- Range of recommended ages for catch-up vaccination
- Range of recommended ages for certain high-risk groups
- Recommended vaccination can begin in this age group
- Recommended vaccination based on shared clinical decision-making
- No recommendation/not applicable

**Important:**
- For those who fall behind or start late, catch-up vaccination is recommended at the earliest opportunity.
- Minimum intervals between doses are indicated by green bars.
- Additional guidance and considerations for specific conditions and situations are provided in the notes section.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Children age 4 months through 6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
<td>Dose 3 to Dose 4</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Birth 4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks</td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 weeks Maximum age for first dose is 14 weeks 6 days</td>
<td>4 weeks 4 weeks maximum age for final dose is 8 months 6 days</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis</td>
<td>6 weeks 4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>6 weeks No further doses needed if first dose was administered at age 15 months or older 4 weeks if first dose was administered before the 1st birthday 8 weeks (as final dose) if first dose was administered at age 12 through 14 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks No further doses needed for healthy children if first dose was administered at age 24 months or older 4 weeks if first dose was administered before the 1st birthday 8 weeks (as final dose for healthy children) if first dose was administered at the 1st birthday or after</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks 4 weeks 4 weeks if current age is &lt;4 years 6 months (as final dose) if current age is 4 years or older</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mumps, mumps, rubella</td>
<td>12 months 4 weeks 3 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months 3 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months 8 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2024**

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Table 1 and the Notes that follow.

**Children age 7 through 18 years**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Children and adolescents age 7 through 18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Not applicable (N/A) 8 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, tetanus, diphtheria, and acellular pertussis</td>
<td>7 years 4 weeks if first dose of DTap/DT was administered before the 1st birthday 6 months (as final dose) if first dose of DTap/DT or TdA/Td was administered at or after the 1st birthday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>9 years Routine dosing intervals are recommended.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>N/A 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>N/A 6 months 8 weeks and at least 16 weeks after first dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>N/A 4 weeks 6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>N/A 4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>N/A 3 months if younger than age 13 years 4 weeks if age 13 years or older</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dengue</td>
<td>9 years 6 months 6 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Table 3**

Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See Notes for medical conditions not listed.

<table>
<thead>
<tr>
<th>Vaccine and other immunizing agents</th>
<th>Pregnancy</th>
<th>Immune compromised (excluding HIV infection)</th>
<th>HIV infection CD4 percentage and count</th>
<th>CIE leak or cochlear implant</th>
<th>Asplenia or persistent complement deficiencies</th>
<th>Heart disease or chronic lung disease</th>
<th>Kidney failure, End-stage renal disease or on Dialysis</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV-mAb (olivevirab)</td>
<td>2nd RSV season</td>
<td>1 dose depending on maternal RSV vaccination status, See Notes</td>
<td>2nd RSV season for chronic lung disease (See Notes)</td>
<td>1 dose depending on maternal RSV vaccination status, See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>SCID*</td>
<td>1 dose each pregnancy</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTaP/PRP/Inactivated</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>HSCT: 3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAIV4</td>
<td></td>
<td></td>
<td>Asthma, wheezing: 2–4 years*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>3 dose series, See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSV (Abbyse)</td>
<td>Seasonal administration, See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dengue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mpos</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Recommended for all age-eligible children who lack documentation of a complete vaccination series | Not recommended for all children, but is recommended for some children based on increased risk for or severe outcomes from disease | Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes. | Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction | Contraindicated or not recommended after pregnancy, if indicated | No Guidance/ Not Applicable |

a. For additional information regarding the laboratory evaluation and use of the vaccines, see the National Advisory Committee for Immunization Practices (NACI) Advisory Committee on Immunization Practices Recommendations for immunization, "Altered Immunocompetence," at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-3 footnote i at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html.

b. Severe Combined Immunodeficiency

c. LAIV4 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months.
The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except dengue, PPSV23, RSV, and COVID-19 vaccines. COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2024

**Notes**

**Human papillomavirus vaccination**

**Routine and catch-up vaccination**

HPV vaccination is routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination is recommended for all persons through age 21 years if not adequately vaccinated.

- 2- or 3-dose series depending on age at initial vaccination:
  - Age 9–14 years at initial vaccination: 3-dose series at 0, 4–6 months; minimum interval: 5 months; repeat dose if administered too soon.
  - Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months; minimum interval: 3 months; repeat dose if administered too soon.

**Special situations**

- Close contacts (e.g., household contacts) of severely immunocompromised persons who require a protected environment: these persons should receive LAIV, if LAIV is given, they should avoid contact with for such immunocompromised persons for 7 days after vaccination.

**Note:** Persons with an egg allergy can receive any influenza vaccine (egg-based and non-egg-based) appropriate for age and health status.

**Influenza vaccination**

**Minimum age:** 6 months (IIV), 2 years (LAIV), 18 years (recombinant Influenza Vaccine, RIV4).

**Routine vaccination**

- Use any influenza vaccine appropriate for age and health status annually.
  - Age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2023, or whose influenza vaccination history is unknown: 2 doses, separated by at least 4 weeks. Administer dose 2 even if the child turns 9 years between receipt of dose 1 and dose 2.
  - Age 6–8 years who have received 2 influenza vaccine doses before July 1, 2023: 1 dose.
  - Age 9 years or older: 1 dose.

- For the 2023-2024 season, see www.cdc.gov/mmwr/volumes/71/mm7102a1.htm

Meningococcal serogroup A,C,W,Y vaccination

Minimum age: 2 months (MenACWY-CRM, Menveo), 3 years (MenACWY-TT, MenQuadRI), 10 years (MenACWY-TT/MenB/MpII, Penfliesy)
**Notes**

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2024

---

**Human papillomavirus vaccine (minimum age: 9 years)**

**Routine and catch-up vaccination**
- HPV vaccination routinely recommended for ages 11–12 years and catch-up HPV vaccination recommended for persons through age 18 years if not adequately vaccinated.
- 2- or 3-dose series depending on age at initial vaccination:
  - Age 9–14 years at initial vaccination: 2-dose series at 0, 16–20 weeks.
  - Age 15 years or older at initial vaccination: 3-dose series at 0, 1, 6 months.
- No additional dose recommended at any time if HPV vaccine series has been completed using recommended dosing intervals.

**Meningococcal serogroup A, C, W, Y vaccination (minimum age: 2 months)**

- MenACWY-CRM, Menveo
- MenACWY-TT, MenQuadrix
- MenACWY-TT/MenB: HbP, Penbraya

**Influenza vaccination**
- Minimum age: 6 months (IIV) or 2 years (LaV4), 18 years (recombinant influenza vaccine, RIV)

**Routine vaccination**
- Use any influenza vaccine appropriate for age and health status annually.
  - Age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2023, or whose influenza vaccination history is unknown: 2-dose, separated by at least 4 weeks.

**Special situations**
- International travel:
  - Infants age 6–11 months: 1 dose before departure.
  - Children 12–15 months: 1 dose before departure.
  - Infants age 12–15 months: 1 dose after return.
  - Adolescents 16–18 years: 1 dose before departure.

- Unvaccinated children age 12–15 months: 1 dose after return.

- Influenza vaccination for travelers:
  - Additional doses of RIV (up to 3 doses, if necessary) before departure.

---

**Deleted**
- MenACWY-D (Menactra) recommendations from all sections.

**Added**
- MenABCWY (Penbraya)
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2024

**Meningococcal serogroup B vaccination**

- Minimum age: 10 years (MenB-AC, Bexsero®; MenB-4F, Trumenba®)

**Shared clinical decision-making**

- Adolescents not at increased risk age 16-23 years
- Bexsero - 2-dose series at least 1 month apart
- Trumenba - 2-dose series at least 6 months apart
- If dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2

**Special situations**

- Anatomic or functional asplenia including sickle cell disease, persistent complement component deficiency, complement inhibitors (e.g., eczematous, rheumatoid arthritis use)
- Bexsero - 2-dose series at least 1 month apart
- Trumenba - 6-dose series at 0, 1, 2, 3, 4, 6 months after dose 1
- Administer dose 2 at least 6 months after dose 1
- Administer dose 3 at least 4 months after dose 2

**Note:** Bexsero and Trumenba are not interchangeable. The same product should be used for all doses in a series.

For MenB booster dose recommendations for groups listed under Special situations and in an outbreak setting and additional meningococcal vaccination information, see [www.cdc.gov/meningococcal/vaccines.html](http://www.cdc.gov/meningococcal/vaccines.html).

Children age 10 years or older may receive a dose of Pneumovax® as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day, and a single injection with Pentaxima® is preferred. If using Pentaxima® for dose 1 MenB subsequent MenB doses must be either MenB-AC, Bexsero®, or Pentaxima®. Minimum interval between Pentaxima® doses - 6 months. Children age 10 years or older recommended to receive booster doses of MenACWY and MenB no less than 6 months after a dose of Pentaxima® that includes MenB-AC and MenB-4F (Trumenba) separately.

**Pneumococcal vaccination**

- Minimum age: 6 weeks (PCV13), PCV20; 2 years (PPSV23)

**Routine vaccination with PCV**

- 4-dose series at 2, 4, 6, 12-15 months

**Catch-up vaccination with PCV**

- Healthy children ages 2-4 years with any incomplete* PCV series: 1 dose PCV
- For other catch-up guidance, see Table 2.

**Note:** Either PCV15 or PCV20 can be used when PCV is indicated. PCV20 is not indicated for children who have received 4 doses of PCV13 or PCV15 or another age appropriate complete PCV series.
**Special situations**

- Age 18 years and at risk for Mpox infection: 2-dose series, 28 days apart.
- Risk factors for Mpox infection include:
  - Persons who are gay, bisexual, and other MSM, transgender or nonbinary people who in the past 6 months have had:
    - A new diagnosis of at least 1 sexually transmitted disease.
    - More than 1 sex partner.
    - Sex at a commercial sex venue.
    - Sex in association with a large public event in a geographic area where Mpox transmission is occurring.
    - Persons who are sexual partners of the persons described above.
    - Persons who anticipate experiencing any of the situations described above.
  - Pregnancy: There is currently no ACP recommendation for Jynneos use in pregnancy due to lack of safety data in pregnant persons. Pregnant persons with any risk factor described above may receive Jynneos.

- Added bullet on use of Jynneos in pregnant persons
HEPATITIS B VACCINE

- Routine vaccination:
  - 3-dose series at age 0, 1–2, 6–18 months (use monovalent HepB vaccine for birth dose and any doses administered before age 6 weeks).
  - Additional steps dependent on mother’s HBsAg status.

- Heplisav-B and PreHevbro may be used for catch up for age 18 years and older.

- Heplisav-B not recommended during pregnancy.
• Providers are required to refer pregnant women who are HBsAg-positive within 7 days after receipt of the test result to the local health department for case management.
ROTAVIRUS VACCINE

• Products
  • RotaTeq® (RV5)
  • Rotarix® (RV1)

• Routine Vaccination:
  • Rotarix®: 2-dose series at age 2 and 4 months
  • RotaTeq®: 3-dose series at age 2, 4, and 6 months
  • If any dose in the series is either RotaTeq® or unknown, default to 3-dose series.

• Catch-Up Vaccination:
  • Do not start the series on or after age 15 weeks, 0 days.
  • The maximum age for the final dose is 8 months, 0 days
• Rotavirus (Rotarix™)
  • NO RECONSTITUTION NEEDED!
  • Oral-dosing applicator-only presentation.
  • FDA approved in Nov 2022.
  • There are 2 variations of live vaccine Rotarix available until 2025 when older lyophilized formulation will retire.
  • Use up current 1ml lyophilized formulation (requires reconstitution) prior to using new liquid formulation.
DTAP/TDAP

- DTaP: 5-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster doses at ages 15–18 months and 4–6 years)
  - Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3
  - Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3
- Tdap: Age 11–12 years: 1 dose Tdap (adolescent booster)
- Catch-Up Vaccination:
  - DTaP: Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3
  - Tdap: Dependent on age and DTaP vaccination history
HIB

• Products: ActHIB®, Hiberix®, Pentacel®, PedvaxHIB® or Vaxelis®

• Routine Vaccination
  • 4-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12–15 months)
    • Vaxelis® is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
  • PedvaxHIB®: 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12–15 months)

• Catch-Up Vaccination
  • Refer to catch up schedule: Dependent on age and vaccination history
PNEUMOCOCCAL VACCINE

• Products:
  • Pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) – ACIP has not made a preferential statement.
  • Pneumococcal polysaccharide vaccine (PPSV23).

• Routine Vaccination with PCV:
  • 4-dose series at 2, 4, 6, 12–15 months.

• Catch-Up Vaccination with PCV:
  • Healthy children ages 2–4 years with any incomplete* PCV series: 1 dose PCV.
  • Note: Either PCV15 or PCV20 can be used when PCV is indicated. For children without risk conditions, PCV20 is not indicated if they have received 4 doses of PCV13 or PCV15 or another age-appropriate complete PCV series.
• PCV13 is no longer distributed or recommended for use in the U.S.

• Pneumococcal polysaccharide vaccine PPSV23 (Pneumovax23, Merck)
  • No longer routinely recommended for all children and adolescents aged ≥2 years at increased risk for invasive pneumococcal disease. It is still recommended in certain circumstances.
POLIO VACCINE

• Routine Vaccination:
  • 4-dose series at ages 2, 4, 6–18 months, 4–6 years
  • 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. A final dose between 4 – 6 years of age is recommended.

• Catch-Up Vaccination:
  • In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
  • Adolescents aged 18 years known or suspected to be unvaccinated or incompletely vaccinated: administer remaining doses (1, 2, or 3 IPV doses) to complete a 3-dose primary series.
**POLIO VACCINE**

- Doses of OPV administered on or after April 1, 2016, do not count towards the U.S. vaccination requirements.

- Related to polio eradication strategy, OPV administered on or after April 1, 2016 are either bOPV (used in routine vaccination and campaigns), or mOPV (used in a type-specific outbreak response).

- These doses do not count towards the U.S. vaccination requirements for protection against all three poliovirus types.

- Persons aged <18 years with doses of OPV that do not count towards the U.S. vaccination requirements should receive IPV to complete the schedule according to the U.S. IPV schedule. [https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm](https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm)
MMR VACCINE

• Products:
  • M-M-R II® (MMR)
  • PRIORIX® (GSK)
  • ProQuad® (MMRV)

• Routine Vaccination:
  • 2-dose series at age 12–15 months, age 4–6 years
  • MMR or MMRV* may be administered
    • For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately because there was a slight increase in febrile seizures seen in the combination vaccine
    • MMRV may be used if parents or caregivers express a preference. If MMRV is used, the minimum interval between MMRV doses is 3 months
MMR VACCINE

Catch Up Vaccination:

• Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart.
• The maximum age for use of MMRV* is 12 years.

*Note: If MMRV is used, the minimum interval between MMRV doses is 3 months.
MEASLES OUTBREAK IN ILLINOIS

• In the context of community measles transmission the 2\textsuperscript{nd} MMR dose can be administered as soon as 28 days after the 1\textsuperscript{st} dose.

• This “accelerated” 2\textsuperscript{nd} dose of MMR meets Illinois’ vaccination requirements for school enrollment.
Infants aged 6–11 months who are traveling should receive an early dose before departure.

- They should then follow the recommended schedule to get another dose at 12–15 months and a final dose at 4–6 years.
VARICELLA

• Routine Vaccination:
  • 2-dose series at age 12–15 months, 4–6 years.
  • VAR or MMRV* may be administered.
  * Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4 weeks may be counted as valid).

• Catch-Up Vaccination:
  • Ensure persons aged 7–18 years without evidence of immunity have a 2-dose series.
HEPATITIS A

• Routine Vaccination:
  • 2-dose series (minimum interval: 6 months) at age 12–23 months.
  • Never need to restart the series you pick up where you left off (same with Hep B).

• Catch-Up Vaccination:
  • Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
  • Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
  • Twinrix® (HepA and HepB vaccine): 18 years or older.
    • 3-dose series (0, 1, and 6 months) or
    • 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months.

*May give Hep A for travel to infants as young as 6 if traveling internationally, but doses administered to infants 6-11 months old do not count toward the routine 2-dose series.
HPV

- HPV vaccination is cancer prevention.
  - Cervical, oropharyngeal, anal, and others.
- Recommended for both girls and boys.
- Routinely recommended starting at 11 years but administration can start at 9 years.
  - Starting HPV vaccine discussions at age 9 years gives more time for parents to make the decision to vaccinate.
If your child is 9- to 14-years-old, your child's doctor will determine whether your child needs a 2-dose or 3-dose schedule of GARDASIL 9.

2 doses

- OR -

3 doses

For individuals 15- to 45-years-old

3 doses

If the second shot is given earlier than 5 months after the first shot, your child will need to get a third shot at least 4 months after the second shot was given.

MENINGOCOCCAL VACCINES

• Products:
  • Meningococcal conjugate or MenACWY vaccines (Menveo® and MenQuadfi®).
  • Serogroup B meningococcal or MenB vaccines (Bexsero® and Trumenba®).
  • Combination: Pentavalent meningococcal or MenABCWY vaccine (PenbrayaTM).

• Routine Vaccination:
  • 2-dose series at age 11-12 years; 16 years.

• Catch-Up Vaccination:
  • Age 13-15 years; 1 dose now and booster at age 16-18 years (minimum interval: 8 weeks).
  • Age 16-18 years: 1 dose.
MENINGOCOCCAL VACCINES CONT.

- MenACWY (Menactra) no longer recommended or distributed.
- Pfizer’s pentavalent meningococcal vaccine (Penbraya) approved by ACIP in October 2023 for use in adolescents and young adults ages 10 to 25 years. The vaccine includes serogroups A, B, C, W, and Y.
  - Approved for the VFC program.
- MenQuadfi® and Menveo can be given regardless of DTaP.
- MenACWY vaccines may be administered simultaneously with MenB vaccines if indicated, but at a different anatomic site, if feasible.
- In children under 10 years needing a meningitis vaccine for increased risk, Menveo liquid (one-vial presentation) is not appropriate for use.
• Pentavalent (MenABCWY) meningococcal vaccine approved for use in adolescents 16 years of age and older.

• Allows full meningococcal vaccine series to be completed in 3 injections instead of 4.

• Prenbraya must be followed by Trumenba and not other MenB vaccine products.
LIVE-ATTENUATED VACCINES

• When possible, give first doses of MMR and Varicella at the same encounter.
  • If these live-attenuated vaccines are not given on the same day, the patient must wait 28 days before receiving the other live-attenuated vaccine.
  • If administered before 28 days, the vaccine administered is considered invalid and must be repeated at least 28 days later.

• The 4-day grace period should not be applied to the 4-week interval between two different live vaccines.
QUESTIONS?
LUNCH & NETWORKING

Please return at 12:10!
RESPIRATORY VIRUS SEASON

Jennifer Burns, APN
AFTER THIS SESSION:

Participants will be able to:

2. Outline products available to prevent respiratory viruses.
RESPIRATORY VIRUS SEASON

• Flu
• COVID-19
• RSV

6 Tips to Prepare Your Practice and Patients for Respiratory Virus Season (CDC)
ILLINOIS DATA

Emergency Department Visits: Percentages by Respiratory Condition | Illinois Facilities

Select any respiratory condition on the color or shape legends below to highlight it in the visualization. Click again to deselect. Your spacebar also toggles the highlight on/off.

- Broad Acute Respiratory Illness
- COVID-19
- Flu
- RSV

Trends in Emergency Department visits for broad acute respiratory conditions, COVID-19, Flu and RSV over the last 3 years. Color and shape of marks identify the different respiratory conditions.

RESPIRATORY VIRUS SEASON TRENDS

Expert projections:

• A similar number of total hospitalizations compared to last year.
• A moderate COVID-19 wave, causing around as many hospitalizations at the peak as occurred at last winter’s peak.
• Influenza season will fall in the typical range of severity.
• RSV is likely to return to normal season patterns following a severe season last year.
BURDEN OF RSV DISEASE

- Most common cause of hospitalization in U.S. infants
- 58,000-80,000 hospitalizations among children <5 years old
- 100–300 deaths in children <5 years old
- 2.1 million outpatient visits
- Risk declines by increasing age throughout infancy and early childhood
- Prematurity and other chronic diseases increase risk of RSV-associated hospitalization, but most hospitalizations are in healthy, term infants

Changes in seasonality of RSV transmission following SARS-CoV2 introduction—NREVSS³, 2017–2023

Abbreviation: PCR = polymerase chain reaction; RSV = respiratory syncytial virus.

* 3-week centered moving averages of percentage of RSV-positive PCR results nationwide. The black dotted line represents the threshold for a seasonal epidemic (3% RSV-positive laboratory PCR results).

[1] https://www.cdc.gov/mmwr/volumes/72/wr/mm7214a1.htm
RSV PREVENTION

- Nirsevimab (Beyfortus) – monoclonal antibody
- Palivizumab (Synagis) – monoclonal antibody
- Abrysvo – Vaccine
- Arexvy – Vaccine
NIRSEVIMAB

- Recommended for ALL infants 7 months and younger who are born shortly before/during RSV season or entering their first RSV season.
- Administer 1 appropriate dose (weight-based) within 1 week of birth if:
  - Mother did not receive Abrysvo
  - Mother’s vaccination status is unknown
  - Mother received Abrysvo less than 14 days before delivery
NIRSEVIMAB

- Recommended for children 8 - 19 months who are entering their second RSV season, regardless of maternal RSV vaccination, who:
  - Have chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen).
  - Are severely immunocompromised.
  - Have cystic fibrosis who have either 1) manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable), or 2) weight-for-length <10th percentile.
  - Are American Indian or Alaska Native.
NIRSEVIMAB ADMINISTRATION

- May be given concomitantly with childhood vaccines.
  - Administer in separate syringes, at different injection sites.
- Palivizumab should not be administered if nirsevimab was administered in the same season.
- If palivizumab was administered initially for the RSV season and < 5 doses were administered, 1 dose of nirsevimab may be administered. No further palivizumab should be administered.
- Nirsevimab may be administered before or during the second RSV season in children 8-19 months old who are eligible for nirsevimab and who received palivizumab in their first RSV season.
- Report to MedWatch: The FDA Safety Information and Adverse Event Reporting Program instead of VAERS.
# TIMING OF ADMINISTRATION

<table>
<thead>
<tr>
<th>Administration Setting</th>
<th>Administration Timing</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>Aug</th>
<th>Sept</th>
<th>Oct</th>
<th>Nov</th>
<th>Dec</th>
<th>Jan</th>
<th>Feb</th>
<th>March</th>
</tr>
</thead>
<tbody>
<tr>
<td>During RSV Season (Oct-Mar)</td>
<td>Hospital (or within 1 week of discharge)</td>
<td>1 dose at birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outside RSV season (Apr-Sept)</td>
<td>Office</td>
<td>1 dose prior to start of their first RSV season</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Chart adapted from Sanofi’s RSV National Expert Program
**ABRYSVO (PFIZER)**

- Only approved RSV vaccine for pregnant people.
- One dose should be administered during RSV season (September-January) for those between 32 – 36 weeks gestation.
- No data on revaccinating with every pregnancy – studies are ongoing.
KNOWLEDGE CHECK

Which product is recommended for all infants 8 months and younger?
A. Abrysvo
B. Nirsevimab
C. Arexvy
COVID-19

• All VFC providers are required to stock and recommend COVID-19 vaccines.

• 2023 – 2024 Pfizer, Moderna, and Novavax COVID-19 vaccines were authorized and recommended in September 2023.

• Everyone 6 months and older should receive a COVID-19 vaccine.
  • Most people only require one dose.
  • Children 6 months to 4 years will need multiple doses if they are starting a series or having not completed a primary series.

Dosing charts
COVID-19 VACCINE AVAILABILITY

- Novavax: CDC discontinued provider ordering on April 30, 2024.
- Pfizer
  - Latest 2023-2024 expiry is 7/31/2024 (6m-4yo) and 8/31/2024 (5-11y and 12yo+ refrigerated/never frozen).
  - Pfizer estimates supply will run out as soon as early May for 6m-4yo, end of contract (June 6) for 5-11yo and late May/early June for 12yo+.
  - CDC will continue provider orders for 6m-4yo until Pfizer’s inventory for CDC is depleted, for 5-11yo until June 6, and for 12yo+ until Pfizer’s inventory for CDC is depleted.
- Moderna
  - Latest 2023-2024 expiry for 6m-11yo and 12yo+ vaccines is late September or better.
  - Moderna indicates supply sufficient to meet demand between now and when 2024-2025 vaccine is available.
COVID-19 FALL 2024 GUIDANCE

• Bridge Program is ending in August 2024 (exact date to be determined).
  • Until the end of the program, adults can continue to locate a free COVID-19 bridge vaccine at www.vaccines.gov.
  • In the coming months, IDPH will provide additional communication and operational guidance to its providers as the program ends.

• June 5, 2024: FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that it DOES recommend the 2024-2025 formula of COVID-19 vaccines to be a monovalent KP.2 strain, if possible.
  • If impossible, use JN.1 strain.
  • This recommendation will be shared with the ACIP Committee at their June meeting.

• Next ACIP meeting: June 26-28
COVID-19 vaccine administration is seasonal.

A. True
B. False
INFLUENZA VACCINE

• All flu vaccines for the 2024-2025 season are anticipated to be trivalent in the United States.

• AAP continues to recommend everyone 6 months+ be vaccinated and does not express a product preference.
**ANTICIPATED ORDERING**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist</td>
<td>0.2mL single dose sprayer, 10 pack</td>
<td>2-49 years</td>
</tr>
<tr>
<td>GSK</td>
<td>Flulaval</td>
<td>0.5mL single dose syringe, 10 pack</td>
<td>6 months +</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone</td>
<td>0.5mL single dose syringe, 10 pack</td>
<td>6 months +</td>
</tr>
<tr>
<td>Seqirus, Inc</td>
<td>Afluria</td>
<td>0.5mL single dose syringe, 10 pack</td>
<td>36 months +</td>
</tr>
<tr>
<td>Seqirus, Inc</td>
<td>Flucelvax</td>
<td>0.5mL single dose syringe, 10 pack</td>
<td>6 months +</td>
</tr>
</tbody>
</table>
ORDERING INFLUENZA

Small allocations of flu vaccine come in at first. Often ordering goes in this order:

• Pre-book
• Limited quantity ordering
• Regular ordering

More to come! Look out for messages on I-CARE.
LUNCH BREAK!

Resume at 12:00pm
VACCINE HESITANCY

Monica Del Ciello, MPH
AFTER THIS SESSION:

Participants will be able to:

1. Describe vaccine hesitancy, misinformation, and disinformation.
2. Demonstrate strategies for combatting vaccine misinformation and disinformation.
3. Outline ways to discuss vaccine hesitancy with patients.
SCHOOL EXEMPTIONS

- Seeing an increase in school exemptions for vaccinations.
- Illinois allows for medical and religious exemptions only.

https://www.cdc.gov/vaccines/imz-managers/coverage/schoolvaxview/data-reports/index.html
SCHOOL EXEMPTIONS

• If a parent brings a religious exemption form, you are still required to counsel them on:
  1. What vaccines are needed.
  2. Why vaccinating is important.
  3. The dangers of being unvaccinated.

• Up to the school official to decide if their listed objection is valid or not.
MISINFORMATION VS. DISINFORMATION

**Misinformation**

- When people spread misinformation, they often believe the information they are sharing.

**Disinformation**

- Disinformation is crafted and disseminated with the intent to mislead others.
MISINFORMATION ONLINE

• Information ecosystem is changing.
  • Main source of information for most Americans is online sources.
• Misinformation goes farther, faster, deeper, and more broadly than the truth
  • Misinformation thrives online, receiving more retweets, shares, and direct messages.
• Disinformation campaigns are deliberate, often orchestrated, and highly effective in confusing people enough to change behaviors.
POWER OF PROVIDER RECOMMENDATIONS

• 3 in 4 parents say the recommendation of their child’s healthcare provider will be important to their COVID vaccine decision.

• A doctor’s office is the most preferred vaccination location for parents of children who have not received a COVID vaccine.

COVID vaccine conversations

Among parents of kids 3-11:

70% have not discussed COVID vaccine with child’s doctor

Among parents of kids 12-18:

50% have not discussed COVID vaccine with child’s doctor

Source: C.S. Mott Children’s Hospital National Poll on Children’s Health, 2021
STRATEGIES FOR ADDRESSING HESITANCY

Give Your Strong Recommendation

• Healthcare professionals remain the most trusted source for vaccine-related information.

Presumptive Approach

• Start each vaccine conversation with a strong, positive “You are due for x vaccine today.”
STRATEGIES FOR ADDRESSING HESITANCY

Motivational Interviewing

• Readiness scaling to learn what is preventing someone from getting vaccinated.

Show Your Vaccine Confidence

• Display posters in clinic spaces with vaccine confident messages.
• Share your own stories of why you got vaccinated and why you recommend vaccines.